Orthocell has posted its fourth consecutive quarter of record revenue, as the regenerative medicine company continues to expand its reach around the globe.
Orthocell has posted its fourth consecutive quarter of record revenue, as the regenerative medicine company continues to expand its reach around the globe.
Following news last week that it had received regulatory approval to begin selling Striate+ – its dental guided bone regeneration product – in Brazil, John Van Der Wielen-chaired Orthocell told the market its revenue for its latest quarter hit $2.2 million.
This was up 38 per cent from 12 months prior.
Orthocell chief executive and managing director Paul Anderson believes this revenue growth could continue moving forward.
“Our primary focus this quarter has been to ensure we were ready to deliver Remplir sales into the US as soon as practical following receipt of FDA clearance,” Mr Anderson said.
“We’ve been working on the basis we would be successful with the FDA and it was extremely gratifying to see approval come through immediately after the end of the quarter.”
“We expect this to be a significant revenue inflection point for us, so a major component of our activities over this quarter has been on-the-ground in the US with a focus on pre-launch sales activities and ensuring logistics are in place.
“I’m pleased to say we’re ready to go.
“We have also maintained the strong sales levels from the previous quarter and continue to receive excellent feedback from surgeons, which in turns gives us confidence as we enter the US market with Remplir.”
At the end of the March 2025 quarter, Orthocell said it had $31.7 million in the till, which it said would aid its push with Remplir into the US.
Orthocell last traded at $1.41 as of 9.02am AWST.
